Security key
501976104
Kyverna Therapeutics, Inc. - Common Stock (KYTX)
CUSIP: 501976104
Q1 2024 13F Holders as of 31 Mar 2024
- Security type / class
- Equity / Common Stock
- Total 13F shares
- 30,688,965
- Total 13F value
- $762,283,849
- Share change
- +30,628,165
- Put/Call ratio
- 10350%
- SEC-reported price per share
- $24.84
- Number of holders
- 88
- Value change
- +$760,773,578
- Number of buys
- 87
- Shares outstanding
- 60,857,980
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q1 2024
Institutions
88
Top holders
10
KYTX full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q2 2026
Kyverna Therapeutics, Inc. SEC filings
Kyverna Therapeutics, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 501976104
Recent filing periods:
Ownership snapshot
Top reported holders of KYTX - Kyverna Therapeutics, Inc. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Vida Ventures, LLC
Disclosed value leader
—
Comparable rows
0/8
Latest evidence
12 Feb 2024
3/4/5
Some rows are evidence-backed but not safely comparable across classes.
8 rows are not safely comparable across share classes.
Showing 1-6 of 8 holder rows.
Quick read
SEC ownership evidence is available, but the rows are not safely comparable across share classes.
0 of 8 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Vida Ventures, LLC's linked filing trail.
Detailed SEC evidence table Showing 1-6 of 8 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Vida Ventures, LLC |
3/4/5
10%+ Owner
|
—
class O/S missing
|
—
4,777,060 shares
|
— | 12 Feb 2024 |
| GILEAD SCIENCES, INC. |
3/4/5
10%+ Owner
|
—
class O/S missing
|
—
4,126,119 shares
|
— | 12 Feb 2024 |
| Northpond Ventures III GP, LLC |
3/4/5
Former 10% Owner
|
—
class O/S missing
|
—
3,255,426 shares
|
— | 12 Feb 2024 |
| Bain Capital Life Sciences Investors, LLC |
3/4/5
10%+ Owner
|
—
class O/S missing
|
—
3,163,868 shares
|
— | 12 Feb 2024 |
| Westlake BioPartners Fund I, L.P. |
3/4/5
10%+ Owner
|
—
class O/S missing
|
—
735,984 shares
|
— | 12 Feb 2024 |
| Dominique Christian Borie |
3/4/5
President, Research and Development Exhibit 24 - Power of Attorney
|
—
class O/S missing
|
—
449,210 shares
|
— | 07 Feb 2024 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q1 2024
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
88
Shares
30,688,965
Rows available
88
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q1 2024 vs Q1 2024 Across Filers
Q1 2024 holders
88
Q1 2024 holders
88
Holder diff
0
| Investor | Q1 2024 Shares | Q1 2024 Shares | Share Diff | Share Chg % | Q1 2024 value | Q1 2024 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend